2 weeks Ago By Defense World Staff
American Century Companies Inc. increased its holdings in shares of Tyra Biosciences, Inc. ( NASDAQ:TYRA – Free Report ) by 582.
9% in the second quarter, according to its most recent filing with the SEC. The fund owned 170,283 shares of the company’s stock after acquiring an additional 145,346 shares during the period. American Century Companies Inc.
owned about 0.32% of Tyra Biosciences worth $2,723,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds have also recently modified their holdings of the business.
Rhumbline Advisers lifted its stake in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after acquiring an additional 2,574 shares during the last quarter.
Wellington Management Group LLP lifted its stake in shares of Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after acquiring an additional 8,324 shares during the last quarter.
Bank of New York Mellon Corp lifted its stake in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after acquiring an additional 14,352 shares during the last quarter.
Oppenheimer & Co. Inc. bought a new stake in shares of Tyra Biosciences during the 1st quarter worth approximately $977,000.
Finally, Vanguard Group Inc. raised its position in Tyra Biosciences by 18.6% during the 1st quarter.
Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares in the last quarter. 84.
14% of the stock is owned by institutional investors. Wall Street Analyst Weigh In A number of brokerages have weighed in on TYRA. Wedbush reaffirmed an “outperform” rating and set a $28.
00 target price on shares of Tyra Biosciences in a research report on Thursday, August 8th. Piper Sandler started coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.
00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a report on Wednesday, July 3rd.
Finally, Oppenheimer lifted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th.
One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.
40. Tyra Biosciences Stock Performance Shares of TYRA opened at $23.34 on Friday.
The stock has a 50-day moving average of $21.62 and a two-hundred day moving average of $18.86.
Tyra Biosciences, Inc. has a one year low of $10.38 and a one year high of $25.
14. The stock has a market cap of $1.23 billion, a P/E ratio of -13.
89 and a beta of 1.01. Tyra Biosciences ( NASDAQ:TYRA – Get Free Report ) last issued its quarterly earnings results on Wednesday, August 7th.
The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.
09. Analysts predict that Tyra Biosciences, Inc. will post -1.
53 EPS for the current fiscal year. Insider Activity In other news, CEO Todd Harris sold 10,092 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.
13, for a total value of $243,519.96. Following the completion of the transaction, the chief executive officer now owns 1,479,528 shares of the company’s stock, valued at approximately $35,701,010.
64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Insiders sold a total of 16,390 shares of company stock valued at $396,444 in the last quarter.
15.40% of the stock is currently owned by company insiders. About Tyra Biosciences ( Free Report ) Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. See Also Five stocks we like better than Tyra Biosciences What is the NASDAQ Stock Exchange? Can Costco Stock Hit New Highs as Interest Rates Drop? Why Understanding Call Option Volume is Essential to Successful Options Trading These 3 Stocks Show How to Navigate Declining Consumer Confidence Dividend Screener: How to Evaluate Dividend Stocks Before Buying MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy? Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc.
( NASDAQ:TYRA – Free Report ). Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
